Sung Lee - Genexine Head VP
| 095700 Stock | KRW 5,880 230.00 4.07% |
Insider
Sung Lee is Head VP of Genexine
| Phone | 82 3 1628 3200 |
| Web | https://www.genexine.com |
Sung Lee Latest Insider Activity
Tracking and analyzing the buying and selling activities of Sung Lee against Genexine stock is an integral part of due diligence when investing in Genexine. Sung Lee insider activity provides valuable insight into whether Genexine is net buyers or sellers over its current business cycle. Note, Genexine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Genexine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Sung Lee over six months ago Acquisition by Sung Lee of 40000 shares of Vir Biotechnology subject to Rule 16b-3 | ||
Sung Lee over six months ago Disposition of 6008 shares by Sung Lee of Vir Biotechnology at 9.8875 subject to Rule 16b-3 |
Genexine Management Efficiency
The company has return on total asset (ROA) of (0.0172) % which means that it has lost $0.0172 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (10.0578) %, meaning that it generated substantial loss on money invested by shareholders. Genexine's management efficiency ratios could be used to measure how well Genexine manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 10 records | INSIDER Age | ||
| HyunHo Jung | Medy Tox | 61 | |
| KiHyuk Yang | Medy Tox | 54 | |
| Lopez Michael | Medy Tox | 62 | |
| Cho Bum | UNISEM Co | 61 | |
| WooSun Lee | Medy Tox | 46 | |
| Kim Kyoon | UNISEM Co | 64 | |
| YongIn Kim | Medy Tox | 61 | |
| Lee Koo | UNISEM Co | 61 | |
| HeeSeok Joo | Medy Tox | 57 | |
| SeungBum Park | Medy Tox | 54 | |
Management Performance
| Return On Equity | -10.06 | |||
| Return On Asset | -0.0172 |
Genexine Leadership Team
Elected by the shareholders, the Genexine's board of directors comprises two types of representatives: Genexine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genexine. The board's role is to monitor Genexine's management team and ensure that shareholders' interests are well served. Genexine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genexine's outside directors are responsible for providing unbiased perspectives on the board's policies.
| You Suh, Head Director | ||
| Jungwon Woo, Chief Officer | ||
| Sung CPA, CFO VP | ||
| Kyu Kim, Ex Bus | ||
| Jae Park, Ex Operation | ||
| Young Sung, Chairman Founder | ||
| JaiHyun Kwon, Director Transaction | ||
| Sung Lee, Head VP |
Genexine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genexine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -10.06 | |||
| Return On Asset | -0.0172 | |||
| Profit Margin | 0.01 % | |||
| Operating Margin | (0.41) % | |||
| Current Valuation | 2.14 T | |||
| Shares Outstanding | 20.55 M | |||
| Shares Owned By Insiders | 21.02 % | |||
| Shares Owned By Institutions | 7.17 % | |||
| Price To Sales | 10.84 X | |||
| Revenue | 36.83 B |
Pair Trading with Genexine
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Genexine position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Genexine will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Genexine could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Genexine when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Genexine - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Genexine to buy it.
The correlation of Genexine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Genexine moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Genexine moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Genexine can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in Genexine Stock
Genexine financial ratios help investors to determine whether Genexine Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Genexine with respect to the benefits of owning Genexine security.